Cherry Medical is developing an analog of HIV TAT protein, called CATS, which stimulates dendritic cell differentiation, and shows efficacy in syngeneic mouse models of breast cancer. The peptide has been tested by others as a monomer, without success. Current efforts have identified the trimer as an active immune-oncology agent. Seeking support to complete process development and replicate efficacy findings.